Relmada Therapeutics Inc reports results for the quarter - Earnings Summary

Relmada Therapeutics

08/11/2024 21:07

* Relmada Therapeutics Inc  RLMD.OQ  reported a quarterly
adjusted
loss of 72 cents​​ per share for the quarter , higher than the
same quarter last year, when the company reported EPS of -73
cents.  The mean expectation of four analysts for the quarter
was for a loss of 64 cents per share. Wall Street expected
results to range from -66 cents to -62 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Relmada Therapeutics Inc's reported EPS for the quarter
was a
loss of 72 cents​.
    * The company reported a quarterly loss of $21.73 million.
    * Relmada Therapeutics Inc shares had risen by 0.6% this
quarter and lost 21.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Relmada
Therapeutics Inc is 11.50 
This summary was machine generated from LSEG data November 8 at
09:07 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.64          -0.72          Missed
 Jun. 30 2024      -0.83          -0.59          Beat
 Mar. 31 2024      -0.85          -0.72          Beat
 Dec. 31 2023      -0.83          -0.84          Missed